Excess deaths to continue constraining recovery of TAVR market in 2023: Goldman

The recovery of structural heart procedures such as transcatheter aortic valve replacement (TAVR) will continue to lag the broader medtech industry next year, according to analysts at Goldman Sachs. Edwards Lifesciences competes with Medtronic for the TAVR market.